Effect of Empagliflozin on Inflammation for Coronary Patients
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests if the diabetes drug empagliflozin can help reduce inflammation in people with stable coronary artery disease who are planning to have a stent placed. It may offer a new way to protect heart health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stable coronary artery disease (CAD) and are scheduled to have a stent placed (PCI) for a new blockage in a natural heart artery.
- You have not taken any SGLT-2 inhibitor medication (like empagliflozin or similar drugs) in the past month.
- You are not currently on anti-inflammatory medications such as steroids, NSAIDs, or immune-suppressing drugs.
- You do not have an inflammatory condition like rheumatoid arthritis, an active infection, or active cancer.
- You have not had a heart attack or unstable chest pain in the last month.
- Your kidney function is good (estimated creatinine clearance above 30 mL/min).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests canagliflozin to see if it lowers “vascular inflammation” in people with diabetes and stable coronary artery disease. It may help reduce harmful inflammation signals that can raise future heart risk.
This trial tests whether a diabetes medication, called an SGLT2 inhibitor, can reduce inflammation around heart arteries in people who have had a heart attack but do not have diabetes. The study uses a special heart scan to look at changes over time.
This trial tests whether giving empagliflozin (a diabetes drug also used for heart failure) before, during, or after an emergency angioplasty for a first heart attack can improve recovery. It is for South Asian patients who are having a first heart attack.
This study tests whether a medication called empagliflozin (a type of drug that helps protect the kidneys) can improve blood vessel health in people with chronic kidney disease who do not have diabetes. It may help slow kidney decline and reduce heart risks.
This study tests whether a diabetes medication called an SGLT2 inhibitor can reduce inflammation in body fat and improve blood vessel function in people with metabolic syndrome. It may help prevent heart disease and other complications.
This study tests whether a diabetes drug (empagliflozin) can improve the heart's ability to relax and fill with blood in people with non-obstructive hypertrophic cardiomyopathy, a type of heart muscle thickening. You may be able to join if you have this condition and are not currently taking an SGLT2 inhibitor.
Hear when a new Inflamation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.